Cargando…

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

BACKGROUND: Migraine pain relief is reported by more than 50% of patients who receive low dose (3 mg) of sumatriptan. Currently, there is no two-step autoinjector of low-dose sumatriptan available on the market for acute migraine treatment. To fulfill this need, a fully assembled, single-dose, subcu...

Descripción completa

Detalles Bibliográficos
Autores principales: Brand-Schieber, Elimor, Munjal, Sagar, Kumar, Rajesh, Andre, Anthony D, Valladao, Will, Ramirez, Margarita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892851/
https://www.ncbi.nlm.nih.gov/pubmed/27313479
http://dx.doi.org/10.2147/MDER.S105899
_version_ 1782435462137249792
author Brand-Schieber, Elimor
Munjal, Sagar
Kumar, Rajesh
Andre, Anthony D
Valladao, Will
Ramirez, Margarita
author_facet Brand-Schieber, Elimor
Munjal, Sagar
Kumar, Rajesh
Andre, Anthony D
Valladao, Will
Ramirez, Margarita
author_sort Brand-Schieber, Elimor
collection PubMed
description BACKGROUND: Migraine pain relief is reported by more than 50% of patients who receive low dose (3 mg) of sumatriptan. Currently, there is no two-step autoinjector of low-dose sumatriptan available on the market for acute migraine treatment. To fulfill this need, a fully assembled, single-dose, subcutaneous autoinjector (sumatriptan 3 mg; product-code DFN-11) was developed. The device allows for injection with a simple two-step, push-to-inject process and provides feedback of the injection activation, progress, and completion. OBJECTIVE: To determine if DFN-11 autoinjector can be used correctly and safely by migraine patients. METHODS AND PARTICIPANTS: A human factors validation study was conducted with 45 migraine patients (30 oral-only medications users; 15 injectable sumatriptan users) who performed one unaided simulated injection. Two days prior, half the oral participants were briefly trained. All others were only given the device to inspect and written instructions to review. No injections were performed during the initial session. All participants received written instructions at the injection session. RESULTS: All participants (45/45; 100%) performed the injection without any errors. Objective measures included device removal from packaging, cap removal, expiration date check, inspection of fluid in window, identification of allowable injection site, proper device positioning, dose confirmation, and device disposal. All participants (45/45; 100%) reported no difficulty administering the injection and no concerns about using the autoinjector during a severe migraine onset. CONCLUSION: The results showed that the DFN-11 autoinjector can be used with safe handling without patterns of confusion, failures, high-risk errors, wet injections, or patient safety risks. The DFN-11 autoinjector was validated to be used correctly and safely by migraine patients, whether they were injection experienced, unexperienced, trained, or self-trained.
format Online
Article
Text
id pubmed-4892851
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48928512016-06-16 Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients Brand-Schieber, Elimor Munjal, Sagar Kumar, Rajesh Andre, Anthony D Valladao, Will Ramirez, Margarita Med Devices (Auckl) Original Research BACKGROUND: Migraine pain relief is reported by more than 50% of patients who receive low dose (3 mg) of sumatriptan. Currently, there is no two-step autoinjector of low-dose sumatriptan available on the market for acute migraine treatment. To fulfill this need, a fully assembled, single-dose, subcutaneous autoinjector (sumatriptan 3 mg; product-code DFN-11) was developed. The device allows for injection with a simple two-step, push-to-inject process and provides feedback of the injection activation, progress, and completion. OBJECTIVE: To determine if DFN-11 autoinjector can be used correctly and safely by migraine patients. METHODS AND PARTICIPANTS: A human factors validation study was conducted with 45 migraine patients (30 oral-only medications users; 15 injectable sumatriptan users) who performed one unaided simulated injection. Two days prior, half the oral participants were briefly trained. All others were only given the device to inspect and written instructions to review. No injections were performed during the initial session. All participants received written instructions at the injection session. RESULTS: All participants (45/45; 100%) performed the injection without any errors. Objective measures included device removal from packaging, cap removal, expiration date check, inspection of fluid in window, identification of allowable injection site, proper device positioning, dose confirmation, and device disposal. All participants (45/45; 100%) reported no difficulty administering the injection and no concerns about using the autoinjector during a severe migraine onset. CONCLUSION: The results showed that the DFN-11 autoinjector can be used with safe handling without patterns of confusion, failures, high-risk errors, wet injections, or patient safety risks. The DFN-11 autoinjector was validated to be used correctly and safely by migraine patients, whether they were injection experienced, unexperienced, trained, or self-trained. Dove Medical Press 2016-05-30 /pmc/articles/PMC4892851/ /pubmed/27313479 http://dx.doi.org/10.2147/MDER.S105899 Text en © 2016 Brand-Schieber et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Brand-Schieber, Elimor
Munjal, Sagar
Kumar, Rajesh
Andre, Anthony D
Valladao, Will
Ramirez, Margarita
Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
title Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
title_full Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
title_fullStr Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
title_full_unstemmed Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
title_short Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
title_sort human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892851/
https://www.ncbi.nlm.nih.gov/pubmed/27313479
http://dx.doi.org/10.2147/MDER.S105899
work_keys_str_mv AT brandschieberelimor humanfactorsvalidationstudyof3mgsumatriptanautoinjectorformigrainepatients
AT munjalsagar humanfactorsvalidationstudyof3mgsumatriptanautoinjectorformigrainepatients
AT kumarrajesh humanfactorsvalidationstudyof3mgsumatriptanautoinjectorformigrainepatients
AT andreanthonyd humanfactorsvalidationstudyof3mgsumatriptanautoinjectorformigrainepatients
AT valladaowill humanfactorsvalidationstudyof3mgsumatriptanautoinjectorformigrainepatients
AT ramirezmargarita humanfactorsvalidationstudyof3mgsumatriptanautoinjectorformigrainepatients